Skip to main content
. 2017 Feb 28;23(8):1489–1496. doi: 10.3748/wjg.v23.i8.1489

Figure 4.

Figure 4

Comparisons of infliximab trough levels and antibody to infliximab levels in patients with/without immunomodulators. There were no differences in the median infliximab trough level (IFX-TL) (0.632 μg/mL and 1.150 μg/mL, respectively; P = 0.274) (A) and median antibodies to infliximab (ATIs) (8.655 AU/mL and 9.017 AU/mL, respectively; P = 0.083) (B) levels between the 2 groups according to the use of concomitant immunomodulators.